title: Ocular adnexal marginal zone B cell lymphoma infiltrated by IgG4-positive plasma cells.
abstract: OBJECTIVE
  To report the clinicopathological characteristics of patients with ocular adnexal marginal zone B cell lymphoma (MZBL) with IgG4-positive plasma cells.
  
  
  METHODS
  114 biopsy samples of ocular adnexal MZBLs were analysed. MZBLs with IgG4-positive plasma cells were included when the IgG4:IgG ratio was >40% (IgG4-related group). The serum levels of each subclass of immunoglobulins and soluble interleukin-2 receptor in the IgG4-related group were compared with those in 61 consecutive patients having MZBL without IgG4-positive plasma cells (IgG4-unrelated group). They were also compared with those in 10 patients having ocular adnexal IgG4-related lymphoplasmacytic disorder (IgG4-related inflammatory group).
  
  
  RESULTS
  Ten (9%) of the patients were diagnosed with MZBL with IgG4-positive plasma cells. The IgG4-related group had a significantly greater degree of sclerosis and reactive follicles in the MZBLs (p=0.0004 and p=0.01, respectively). The serum levels of IgG, IgG1, IgG4, IgE and soluble interleukin 2 receptor in the IgG4-related group were significantly higher than those in the IgG4-unrelated group (p=0.003, p=0.009, p<0.0001, p<0.0001 and p=0.0007, respectively). The serum levels did not differ significantly from those of the IgG4-related inflammatory group. The IgG4-related group also had reactive IgG4-positive lymphoplasmacytic infiltrations in the recurrent lesion and in the stomach.
  
  
  CONCLUSIONS
  IgG4-positive plasma cells had infiltrated into ocular adnexal MZBLs in 9% of cases. It is suggested that ocular adnexal MZBLs with IgG4-positive plasma cells have unique histological and serological characteristics that overlap those of ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder and systemic conditions.
authors.affiliation: Department of Ophthalmology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan. ganiky@nnh.hosp.go.jp
authors.forename: Toshinobu
authors.initials: T
authors.lastname: Kubota
authors.forename: Suzuko
authors.initials: S
authors.lastname: Moritani
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yoshino
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagai
authors.forename: Hiroko
authors.initials: H
authors.lastname: Terasaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005134:Eye Neoplasms / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000032:analysis* / Q000097:blood; D018442:Lymphoma, B-Cell, Marginal Zone / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010950:Plasma Cells / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000097:blood; D012008:Recurrence; D012598:Sclerosis; D013274:Stomach Neoplasms / Q000276:immunology
chemical_list: D007074:Immunoglobulin G; D015375:Receptors, Interleukin-2; D007073:Immunoglobulin E